Literature DB >> 8858711

Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders.

S Michelini1, G B Cassano, F Frare, G Perugi.   

Abstract

This paper reviews the literature on the epidemiological, biological and clinical features of benzodiazepine dependence and withdrawal syndrome, focusing on clinical problems associated with the long-term use of benzodiazepine (BZs) in mood and anxiety disorders. These conditions represent the most frequent mental disorders for which BZs are overprescribed. In addition to dependence and withdrawal phenomena, the presence of chronic subtle toxicity and the interference with the underlying psychopathology observed with BZ use suggests a need for a more careful evaluation of the risk-benefit ratio in the long-term administration of BZs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858711     DOI: 10.1055/s-2007-979558

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  22 in total

Review 1.  Recent progress of isocyanide-based multicomponent reactions in Iran.

Authors:  Ahmad Shaabani; Ali Maleki; Ali Hossein Rezayan; Afshin Sarvary
Journal:  Mol Divers       Date:  2010-07-29       Impact factor: 2.943

2.  BDNF plasma levels decrease during benzodiazepine withdrawal in patients suffering from comorbidity of depressive disorder and benzodiazepine dependence.

Authors:  Annemarie Heberlein; Bernd Lenz; Marc Muschler; Helge Frieling; Rebecca Buechl; Michael Gröschl; Johannes Kornhuber; Stefan Bleich; Thomas Hillemacher
Journal:  Psychopharmacology (Berl)       Date:  2010-02-06       Impact factor: 4.530

3.  Microwave-assisted multicomponent reaction in water leading to highly regioselective formation of benzo[f]azulen-1-ones.

Authors:  Shu-Liang Wang; Chuang Cheng; Fei-Yue Wu; Bo Jiang; Feng Shi; Shu-Jiang Tu; Trideep Rajale; Guigen Li
Journal:  Tetrahedron       Date:  2011-06-24       Impact factor: 2.457

4.  The use of an electronic clinical rule to discontinue chronically used benzodiazepines and related Z drugs.

Authors:  C Mestres Gonzalvo; V Milosevic; B P C van Oijen; H A J M de Wit; K P G M Hurkens; W J Mulder; R Janknegt; J M G A Schols; F R Verhey; B Winkens; P H M van der Kuy
Journal:  Eur J Clin Pharmacol       Date:  2017-11-10       Impact factor: 2.953

5.  Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial.

Authors:  Jerome H Taylor; Ewgeni Jakubovski; Michael H Bloch
Journal:  J Psychiatr Res       Date:  2015-04-04       Impact factor: 4.791

Review 6.  [Depression in cancer patients].

Authors:  Barbara Sperner-Unterweger
Journal:  Wien Med Wochenschr       Date:  2015-07-04

7.  Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.

Authors:  Michael W Otto; R Kathryn McHugh; Naomi M Simon; Frank J Farach; John J Worthington; Mark H Pollack
Journal:  Behav Res Ther       Date:  2010-04-28

Review 8.  Role of atypical antipsychotics in the treatment of generalized anxiety disorder.

Authors:  Rachel Hershenberg; Daniel F Gros; Olga Brawman-Mintzer
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

9.  Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

Authors:  Qian Chen; Akira Nakajima; Corbin Meacham; Ya-Ping Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

Review 10.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.